Clinical efficacy and nursing intervention of ceftazidime tazobactam sodium combined with levofloxacin in treating heart failure complicated with pulmonary infection in elderly patients

Abstract

This study aims to probe the clinical efficacy of the nursing intervention of ceftazidime tazobactam sodium combined with Levofloxacin in treating heart failure complicated with lung infection in elderly patients. Patients in the control group (n = 59) accepted ceftazidime tazobactam sodium injection (3:1). Patients in the observation group (n = 59) were given levofloxacin hydrochloride injection based on the control group. Compared with the control group, the total effective rate of the observation group was elevated (Ï2 = 5.94, P < 0.05), levels of inflammatory factors interleukin-4, interleukin-6, and tumor necrosis factor-alpha were lessened (P < 0.05), left ventricular end-systolic diameter together with left ventricular end-diastolic dimension levels were declined (P < 0.05), left ventricular ejection fraction was decreased (P < 0.05), the clearance rate of pathogenic bacteria was higher (P < 0.05), the occurrence of adverse reactions was lessened (P < 0.05). No difference was discovered in the satisfaction rate between both groups (Ï2 = 3.01, P > 0.05). To summarize, Ceftazidime, tazobactam sodium, and Levofloxacin can decline inflammatory factor levels in elderly patients with HF and lung infection. It can effectively correct the condition of body infection and is conducive to improving bacterial clearance rate without increasing adverse reactions.